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Abstract: Background: Patients with coronavirus infectious disease 2019 (COVID-19) and
gastrointestinal symptoms showed increased values of fecal calprotectin (FC). Additionally,
bowel abnormalities were a common finding during abdominal imaging of individuals with COVID-19
despite being asymptomatic. The current pilot study aims at evaluating FC concentrations in patients
without gastrointestinal symptoms. Methods: we enrolled 25 consecutive inpatients with COVID-19
pneumonia, who were admitted without gastrointestinal symptoms and a previous history of
inflammatory bowel disease. Results: At admission, 21 patients showed increased FC with median
values of 116 (87.5; 243.5) mg/kg despite absent gastrointestinal symptoms. We found a strong positive
correlation between FC and D-Dimer (r = 0.745, p < 0.0001). Two patients developed bowel perforation.
Conclusion: our findings may change the current understanding of COVID-19 intestinal-related
disease pathogenesis, shedding new light on the potential role of thrombosis and the consequent
hypoxic intestinal damage.
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1. Main Text
At the time of writing this letter, the principal cause of mortality in patients with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is respiratory failure with exudative diffuse
alveolar damage and massive capillary congestion often accompanied by microthrombi or, in lower
percentages, by generalized thrombotic microangiopathy, as reported by post-mortem examinations [1].
With coronavirus infectious disease 2019 (COVID-19) being conceived as a solely respiratory disease [2,3],
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the scientific community initially assumed that the lungs represented the preferred and initial site of
viral proliferation, as well as its primary source for shedding and transmission.
2. Gastrointestinal Manifestations of COVID-19
Recent findings indicated that SARS-CoV-2 could bind to gastrointestinal cells via specific receptors
(such as the angiotensin converting enzyme-2 (ACE2) receptor and the transmembrane serine protease
2) [4], whose interaction is supposed to promote local inflammation by massive cytokine and chemokine
release [5]. Additionally, an autoptic study on the small intestine of two COVID-19 patients showed
endotheliitis of the submucosa vessels and evidence of direct viral infection of endothelial cells [6].
Regarding the clinical presentation, gastrointestinal symptoms are present in up to 28% of patients
with COVID-19 [7–9], and fecal SARS-CoV-2-RNA was detected in approximately 50% of positive
individuals [8–10]. Recently, Effenberger et al. [5] proposed the role of fecal calprotectin (FC) as a
marker of intestinal inflammation in COVID-19 patients who developed gastrointestinal (GI) symptoms.
In particular, the authors detected significantly higher FC values in patients with acute diarrhea if
compared to patients without diarrhea or with ceased diarrhea (>48 h). In this pilot study, we aimed to
externally validate the results of Effenberger et al. [5] by determining the actual absence of significant
FC concentrations in patients who did not present gastrointestinal symptoms and without previous
history of inflammatory bowel disease (IBD).
3. Materials and Methods
We performed a prospective observational cross-sectional study by enrolling 25 consecutive
COVID-19 inpatients from May 2020 to June 2020, who were admitted without gastrointestinal
symptoms and a previous history of IBD.
SARS-CoV-2 detection in nasopharyngeal swabs was determined by PCR (LightMix®-
Modular-Wuhan CoV-RdRP and E genes). FC concentration was determined by the DiaSorin-
LIAISON®-Calprotectin according to the manufacturer’s specification (normal range <50 mg/kg).
Both tests were performed at admission. Potential infective causes for FC increase were investigated
through canonical stool analysis for common bacteria, viral and parasitic pathogens.
Data were displayed as median (Quartile 1; Quartile 3). We explored the correlation between
continuous variables via Spearman’s correlation coefficient, considering a statistically significant
two-tailed p-value < 0.05.
4. Results
From the 25 original patients, 21 (84%) showed increased FC, with median values of 116 (87.5;
243.5) mg/kg despite being asymptomatic for GI symptoms, and a median D-Dimer of 1.32 (0.82; 2)
mg/L (normal value < 0.5 mg/L). Their clinical characteristics, possible risk factors, and biochemical
parameters are reported in Table 1. We did not detect any significant correlation between FC and the C
reactive protein (CRP), white blood cell count (WBC), platelet count, ferritin, lactate dehydrogenase
(LDH) or albumin. However, we found a strong positive correlation between FC and D-Dimer
(r = 0.745, p < 0.0001).
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Table 1. Patients’ Characteristics and Laboratory Parameters. Continuous Variables are Reported as
the Median (Quartile1; Quartile3). CRP: C Reactive Protein; LDH: Lactate Dehydrogenase.
Characteristics






Age, years 78.3 (69; 81.5) 76 (70; 84)
Gender, Male 15 (71.4%) 3 (75%)
BMI (kg/m2) 24 (21; 27) 25 (20; 26)
Hearth Diseases 10 (47.6%) 2 (50%)
Hypertension 7 (33.3%) 2 (50%)
Previous ACE-Inhibitors 5 (23.8%) 2 (50%)
Active Smokers 7 (33.3%) 1 (25%)
Antibiotic Therapy 5 (23.8%) 1 (25%)
Heparin Therapy 13 (61.9%) 2 (50%)
White Blood Cell Count 6530 (4050; 7350) 6110 (4350; 8365)
Platelets (109/L) 205 (141;357) 189 (153; 265)
PCR (mg/dL) 31 (24; 91) 40 (8; 115)
LDH (U/L) 290 (195; 381) 250 (190; 300)
Ferritin (µg/L) 645 (520; 1210) 550 (420; 610)
Fecal Calprotectin (mg/kg) 116 (87.5; 243.5)
D-Dimer (mg/LFEU) 1.32 (0.82; 2) 0.87 (0.5; 1.23)
4.1. Intestinal Perforation
Two of the enrolled patients developed intestinal perforation. They were admitted to the
emergency department for high-grade fever, cough and dyspnea. Both resulted positive to SARS-CoV-2
in nasopharyngeal swabs, and according to their comorbidities, they were admitted to the hospital.
The first patient, a 68-year-old female with an FC of 216 mg/kg, WBC of 17,940 cells/mm3, CRP of
94 mg/L and D-Dimer of 1.28 mg/LFEU developed severe abdominal pain 20 days after hospital
admission. The contrast-enhanced abdominal computed tomography (CT) showed rectal wall and
sigmoid colon thickening surrounded by extraluminal free air; a small-sized fluid collection and a
smoothly thickened peritoneum were noted. The patient was treated conservatively.
The second patient, an 84-year-old female with an FC of 290 mg/kg, WBC of 5990 cells/mm3, CRP of
290 mg/dL and D-Dimer of 2.1 mg/LFEU developed severe abdominal pain the day after admission
and septic shock. The contrast-enhanced abdominal CT showed rectal wall thickening, with free
air organized circumferentially around the mesorectum, suggestive for retroperitoneal perforation;
an inflammatory stranding of perivisceral fat tissue was also identified. The patient died the next day.
4.2. A Hypothesis on the Role of Thrombosis
In contrast to Effenberger et al. [5], we detected an increase in FC concentration in 88.2% of patients
without GI symptoms. Besides, our findings also represent the first report of a significant positive
correlation between FC and D-Dimer. This particular discovery may change our current understanding
of COVID-19 intestinal-disease pathogenesis, shedding new light on the potential role of thrombosis
and the consequent hypoxic intestinal damage. Indeed, FC is mainly expressed by neutrophils [11],
whose functions are severely affected by intestinal ischemia [12]. The two patients that developed
bowel perforation showed on the CT rectal and sigmoid colon wall thickening. In non-COVID-19
patients, left flexure and sigmoid colon segments have the highest risk of ischemic colitis, while distal
rectum is usually spared due to its dual blood supply; at variance, in COVID-19 patients colon/rectal
Trop. Med. Infect. Dis. 2020, 5, 147 4 of 5
thickening was previously reported in seven cases [13] in agreement with our data, supporting a
relationship between intestinal damage and COVID-19 infection. Notably, D-Dimer was found to
increase in up to 47% of patients with COVID-19 at hospital admission [14], which resulted in higher
mortality rates despite not presenting pulmonary embolism or deep vein thrombosis. Was the gut
being responsible for these patients’ death? Unfortunately, this question has no definitive answer, but
according to a recent study, bowel abnormalities were a common finding (31%) during abdominal
imaging of individuals with COVID-19. Patients who underwent laparotomy often showed histological
ischemia due to small vessel thrombosis [13].
That being said, our data should be taken with caution due to the relatively small sample size
and the possible limitations related to selection bias. While waiting for the additional validation,
and data on gut histopathology (autoptic reports or in vivo endoscopic biopsies) in COVID-19 patients,
we firmly believe that the correlation between FC and D-Dimer may yield the secrets behind the
COVID-19 Pandora’s box.
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